Ceftazidime-Avibactam Dosing for Creatinine Clearance 3 mL/min
For a patient with severe renal impairment (CrCl 3 mL/min), administer ceftazidime-avibactam 0.94 grams (ceftazidime 0.75 grams and avibactam 0.19 grams) intravenously every 48 hours, infused over 2 hours 1.
Dosing Algorithm by Renal Function
The FDA-approved dosing for ceftazidime-avibactam in adults with severe renal impairment follows a clear stratification 1:
- CrCl 31-50 mL/min: 1.25 g every 8 hours
- CrCl 16-30 mL/min: 0.94 g every 12 hours
- CrCl 6-15 mL/min: 0.94 g every 24 hours
- CrCl ≤5 mL/min: 0.94 g every 48 hours
With a creatinine clearance of 3 mL/min, this patient falls into the lowest renal function category, requiring the most extended dosing interval of 48 hours.
Critical Timing Considerations
If the patient is receiving hemodialysis, administer the dose after dialysis on dialysis days 1. Both ceftazidime and avibactam are hemodialyzable, with avibactam showing an extraction coefficient of 0.77 and approximately 55% removal during a 4-hour hemodialysis session 1. Administering before dialysis would result in premature drug removal and subtherapeutic exposure.
Monitoring Requirements
Monitor creatinine clearance at least daily and adjust dosing accordingly 1. This is particularly important because:
- Renal function can improve rapidly in acute kidney injury, potentially requiring dose escalation 2, 3
- The exposure of both ceftazidime and avibactam is highly dependent on renal function 1
- Failure to adjust doses with improving renal function may lead to subtherapeutic concentrations
Important Caveats
Risk of Underdosing
Recent evidence suggests that renal dose reduction of ceftazidime-avibactam may be associated with worse outcomes. One study found that receiving a reduced dose was independently associated with mortality (HR 4.47) in patients with KPC-producing Klebsiella pneumoniae bloodstream infections 4. However, this finding must be balanced against the established FDA dosing recommendations based on pharmacokinetic modeling 1.
Neurotoxicity Risk
While dose reduction is necessary for renal impairment, be aware that even reduced doses can accumulate. In patients receiving continuous renal replacement therapy, 90.48% demonstrated ceftazidime concentrations exceeding the neurotoxicity threshold of 104 mg/L 5. Monitor for neurological symptoms including confusion, seizures, or encephalopathy.
Pediatric Considerations
For pediatric patients ≥2 years with eGFR ≤5 mL/min/1.73m², the dose is 23.75 mg/kg (maximum 0.94 g) every 48 hours 1. There is insufficient information to recommend dosing for pediatric patients <2 years with renal impairment 1, 6.
Administration Details
- Infusion time: Always administer over 2 hours 1
- Preparation: Reconstitute with 10 mL of compatible diluent, then further dilute before infusion 1
- Timing: For hemodialysis patients, give after dialysis to facilitate directly observed therapy and avoid premature removal 1
The recommended 48-hour interval for CrCl ≤5 mL/min represents a 6-fold extension compared to normal renal function dosing, reflecting the near-complete dependence on renal elimination for both components 1.